Education
About Us
Working with TipRanks
Follow Us
Galapagos (GLPG)
NASDAQ:GLPG
GLPG Stock Chart & Stats
Day’s Range― - ―
52-Week Range$22.36 - $31.23
Previous CloseN/A
Volume251.83K
Average Volume (3M)293.40K
Market Cap
$1.65B
Enterprise Value-$1.86B
Total Cash (Recent Filing)€94.65M
Total Debt (Recent Filing)€405.00K
Price to Earnings (P/E)21.2
Beta0.74
Next Earnings
Jul 23, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding65,897,070
10 Day Avg. Volume511,221
30 Day Avg. Volume293,396
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.50
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$25.75Price Target Upside-2.79% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering5
---
Galapagos News
PremiumCompany Announcements
Galapagos NV Reports Q1 2025 Results and Strategic Updates
PremiumCompany Announcements
Galapagos NV Reports Q1 2025 Results and Strategic Developments
PremiumCompany Announcements
Galapagos Announces Leadership Changes Amid Strategic Separation---
Bulls Say, Bears Say
Bulls Say
Financial StabilityThe company expects a cash runway extending to 2028, suggesting financial stability for ongoing projects.
Strategic FocusGLPG is prioritizing the development of GLPG5101 due to logistical advantages, which could streamline the manufacturing process.
Bears Say
Market PerceptionGLPG had been trading at a negative enterprise value as lead pipeline assets are still several years from commercialization with unclear differentiation.
Strategic UncertaintyThe absence of updates on the proposed spinoff indicates uncertainty about the company's strategic direction.
---
Ownership Overview
―
Insiders
2.69% Mutual Funds
0.06% Other Institutional Investors
96.74% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GLPG FAQ
What was Galapagos’s price range in the past 12 months?
Galapagos lowest stock price was $22.36 and its highest was $31.23 in the past 12 months.
What is Galapagos’s market cap?
Galapagos’s market cap is $1.65B.
When is Galapagos’s upcoming earnings report date?
Galapagos’s upcoming earnings report date is Jul 23, 2025 which is in 89 days.
How were Galapagos’s earnings last quarter?
Galapagos released its earnings results on Apr 23, 2025. The company reported -$2.673 earnings per share for the quarter, missing the consensus estimate of -$0.142 by -$2.531.
Is Galapagos overvalued?
According to Wall Street analysts Galapagos’s price is currently Overvalued.
Does Galapagos pay dividends?
Galapagos does not currently pay dividends.
What is Galapagos’s EPS estimate?
Galapagos’s EPS estimate is -0.11.
How many shares outstanding does Galapagos have?
Galapagos has 65,897,070 shares outstanding.
What happened to Galapagos’s price movement after its last earnings report?
Galapagos reported an EPS of -$2.673 in its last earnings report, missing expectations of -$0.142. Following the earnings report the stock price went up 3.882%.
Which hedge fund is a major shareholder of Galapagos?
Currently, no hedge funds are holding shares in GLPG
---
Galapagos Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$25.75 (-2.79% Downside)
$25.75 (-2.79% Downside)
Blogger Sentiment
Bullish
GLPG Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 43.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.4%
Last 30 Days ▲ 1.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.41%
12-Months-Change
Fundamentals
Return on Equity
-6.25%
Trailing 12-Months
Asset Growth
-1.20%
Trailing 12-Months
Company Description
Galapagos
Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company's pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis. In addition, its other pipeline products include GLPG2737, a cystic fibrosis transmembrane conductance regulator that is in Phase 2 clinical trials to treat patients with autosomal dominant polycystic kidney disease; and GLPG0555, a JAK1 inhibitor, which is in Phase 1b for treatment of patients with osteoarthritis. The company has collaboration agreements with Gilead Sciences, Inc.; AbbVie S.à r.l.; and Novartis Pharma AG. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
---
GLPG Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant advancements in cell therapy and strategic initiatives, such as the separation into two entities and key partnerships. However, challenges in manufacturing setup, deprioritization of certain programs, and workforce reductions were noted. The overall sentiment balances between positive strategic steps and the challenges faced.Read More>---
GLPG Stock 12 Month Forecast
Average Price Target
$25.75
▼(-2.79% Downside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Agios Pharma
―
Denali Therapeutics
―
Beam Therapeutics
―
Kymera Therapeutics
―
Best Analysts Covering GLPG
1 Year
1 Year Success Rate
8/8 ratings generated profit
1 Year Average Return
+25.82%
reiterated a sell rating 2 months ago
Copying Jason Gerberry's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.82% per trade.
---